Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Contemporary art collage of hand holding a dart aiming at the target. Business targeting, aiming, focus concept. Modern design. Copy space.

NextGen

Delphia Eyes New Precision Medicine Approach: Activation Lethality

Delphia launched in May 2024 with the goal of forcing malignant cells to overactivate and die.

March 4, 2025

2 min read

Annalee Armstrong

Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.

Depression

Neumora Shakes Up Phase III MDD Trials After January Miss

After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, with data expected in the first half of 2026.

March 3, 2025

1 min read

Dan Samorodnitsky

Glitter Vibrant Spheres Abstract Background Digital Renderingv

Phase III

Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.

March 3, 2025

2 min read

Annalee Armstrong

Pop art Medicine pill or tablet icon isolated on color background. Capsule pill and drug sign. Pharmacy design. Vector Illustration

Pain

Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III trials before long.

March 3, 2025

2 min read

Dan Samorodnitsky

AbbVie's office in South San Francisco, California

Obesity

Obesity Late-Comer AbbVie Inks up to $2.2B Amylin Deal With Gubra

AbbVie is joining the amylin arena, though the pharma is still far behind leaders Novo Nordisk and Eli Lilly.

March 3, 2025

2 min read

Tristan Manalac

Europe

Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that will apply to all EU member states as well as Norway, Liechtenstein and Iceland.

March 3, 2025

2 min read

Tristan Manalac

Beautiful colorful unpeeled peanut pattern on a light blue background. Flat lay arrangement, top view.

Immunology and inflammation

First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader

Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children with one or more food allergies.

March 3, 2025

2 min read

Tristan Manalac